4 Healthcare ETFs to Tap Into Eli Lilly's Post-Q3 Earnings Rally

Eli Lilly (LLY) surged 10.1% after posting better-than-expected Q3 2026 results and raising its 2026 sales guidance, putting the stock back at the center of healthcare positioning.

The engine was Mounjaro and Zepbound, which together generated more than $16 billion in revenue, up $6 billion year over year. That growth pace is what drove the guidance raise and the post-earnings pop.

The catch is valuation. LLY now trades at a P/E of 30.91, a premium multiple that leaves less room for disappointment. That is prompting some investors to look at healthcare ETFs with heavy LLY weightings, including XLV and VHT, as a way to keep exposure to the rally while spreading single-stock risk. HRTS and THNR are also on the list of funds highlighted for that approach.

Interpretation: the ETF angle is a risk-management trade, not a fundamental call. Buyers of XLV and VHT still carry LLY exposure, but the rest of each basket dilutes the premium-multiple risk tied to one name. The funds will not fully escape LLY's moves, though, since the pitch depends on significant LLY weightings.